Skip to search formSkip to main contentSkip to account menu

efavirenz

Known as: (S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one, (S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one, efavirenz, (S)-isomer 
A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
BACKGROUND A new pandemic influenza A (H1N1) virus has emerged, causing illness globally, primarily in younger age groups. To… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well… 
Review
2005
Review
2005
The 2008 BHIVA Guidelines have been updated to incorporate all the new relevant information (including presentations at the 15th… 
Highly Cited
2004
Highly Cited
2004
Objectives: Efavirenz is an effective antiretroviral agent, but central nervous system side effects occur commonly, and… 
Review
2004
Review
2004
BACKGROUND Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alternative to regimens containing… 
Highly Cited
2003
Highly Cited
2002
Highly Cited
2002
Hepatologists are frequently asked to evaluate human immunodeficiency virus (HIV)‐infected patients with abnormal liver enzymes… 
Highly Cited
1999
Highly Cited
1999
BACKGROUND Efavirenz is a nonnucleoside reverse-transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). We…